Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2024-09-27 00:00:00 ET · period of report 2024-09-27 · accession 0001415889-24-024074 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-09-27 | 2024-09-27 | JANX | Campbell David Alan | Pres, CEO, Dir | S - Sale | $46.31 | -25.0K | 307.1K | -8% | -$1.16M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-27 | S | D | 18,957 | $46.09 | 313,097 | D | — | — | (F2) The weighted average sale price for the transaction reported was $46.0893 and the range of prices were between $45.55 and $46.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-09-27 | S | D | 5,248 | $46.86 | 307,849 | D | — | — | (F3) The weighted average sale price for the transaction reported was $46.855 and the range of prices were between $46.565 and $47.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2024-09-27 | S | D | 795 | $47.84 | 307,054 | D | — | — | (F4) The weighted average sale price for the transaction reported was $47.8384 and the range of prices were between $47.56 and $48.135. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |